Amikacin

Amikacin
IUPAC ime
	(2S)-4-amino-N-[(2S,3S,4R,5S)-5-amino-2-; [(2S,3R,4S,5S,6R)-4-amino-3,5-dihidroksi-; 6-(hidroksimetil)oksan-2-il]oksi-4-[(2R,3R,; 4S,5R,6R)-6-(aminometil)-3,4,5-trihidroksi-; oksan-2-il]oksi-3-hidroksi-cikloheksil]-2-hidroksi-; butanamid
Klinički podaci
Prodajno ime	Amikin
Drugs.com	Monografija
MedlinePlus	a682661
Kategorija trudnoće	AU: D ; US: C (Mogući rizik) ; ;
Način primene	Intramuskularno, intravenozno
Pravni status
Pravni status	UK: POM (Samo na recepat) ; US: ℞-only ;
Farmakokinetički podaci
Vezivanje proteina	0-11%
Poluvreme eliminacije	2-3 sata
Izlučivanje	Renalno
Identifikatori
CAS broj	37517-28-5
ATC kod	D06AX12 (WHO) J01GB06, S01AA21
PubChem	CID 37768
DrugBank	DB00479
ChemSpider	34635
UNII	84319SGC3C
KEGG	D02543
ChEBI	CHEBI:2637
ChEMBL	CHEMBL177
Hemijski podaci
Formula	C22H43N5O13
Molarna masa	585,603 g/mol
	SMILES O=C(N[C@H]3[C@H](O[C@H]1O[C@@H]([C@@H](O)[C@H](N)[C@H]1O)CO)[C@@H](O)[C@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](N)C3)[C@@H](O)CCN; ;
	InChI InChI=1S/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1 ; Key:LKCWBDHBTVXHDL-RMDFUYIESA-N ;

Amikacin je aminoglikozidni antibiotik koji se koristi za tretiranje različitih tipova bakterijskih infekcija. Amikacin deluje putem vezivanja za bakterijsku 30S ribozomalnu podjedinicu, čime uzrokuje pogrešno očitavanje iRNK te time onemogućava bakterijsku sintezu proteina koji su vitalni za njen rast.

Medicinske upotrebe уреди

Amikacin se najčešće koristi za tretiranje ozbiljnih, u bolnici stečenih infekcija uzrokovanih gramnegativnim bakterijama otpornim na višestruke lekove kao što su Pseudomonas aeruginosa, Acinetobacter, i Enterobacter. Takođe je efektivan protiv Serratia marcescens i Providencia stuartii. Amikacin se može koristiti za tretiranje netuberkularnih mikobakterijskih infekcija i tuberkuloze (ako je uzrokovana senzitivnim vrstama) kad drugi lekovi nisu uspešni.

Amikacin se može kombinovati sa beta-laktamskim antibioticima za terapiju ljudi sa neutropenijom i groznicom.

Lipozomalni amikacin za inhaliranje je trenutno u završnom stadijumu kliničkih ispitivanja za tretman respiratornih bolesti, kao što je cistična fibroza^[1], Pseudomonas aeruginosa^[2], netuberkularnih mikobakterijskih infekcija^[3] i bronhiektazije.^[4]^[5]

Reference уреди

^ "Randomized, open-label, active-controlled, multicenter study to assess the efficacy, safety and tolerability of Arikace™ in Cystic Fibrosis patients with chronic infection due to Pseudomonas aeruginosa" is a European Phase III clinical trial, being conducted across multiple sites in the EU, starting at the Royal Brompton Hospital, Department of Respiratory Medicine, in London
^ Study to Evaluate Arikace™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
^ "A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikace™) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease" is a Phase II clinical trial in collaboration with the US National Institute of Allergy and Infectious Diseases
^ "A Placebo Controlled, Randomized, Parallel Cohort, Safety And Tolerability Study Of 2 Dose Levels Of Liposomal Amikacin For Inhalation (Arikace™) In Patients With Bronchiectasis Complicated By Chronic Infection Due To Pseudomonas Aeruginosa" Phase II (completed).
^ "A Study to Determine the Safety and Tolerability of Arikace™ Versus Placebo in Patients Who Have Bronchiectasis" Архивирано на сајту Wayback Machine (29. април 2015) is a Phase II clinical trial (as [4]) completed in the UK.

Literatura уреди

Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc. 1999 May;74(5):519-28. Review. PMID 10319086

Spoljašnje veze уреди

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] "Randomized, open-label, active-controlled, multicenter study to assess the efficacy, safety and tolerability of Arikace™ in Cystic Fibrosis patients with chronic infection due to Pseudomonas aeruginosa" is a European Phase III clinical trial, being conducted across multiple sites in the EU, starting at the Royal Brompton Hospital, Department of Respiratory Medicine, in London

[2] Study to Evaluate Arikace™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

[3] "A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (Arikace™) in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease" is a Phase II clinical trial in collaboration with the US National Institute of Allergy and Infectious Diseases

[4] "A Placebo Controlled, Randomized, Parallel Cohort, Safety And Tolerability Study Of 2 Dose Levels Of Liposomal Amikacin For Inhalation (Arikace™) In Patients With Bronchiectasis Complicated By Chronic Infection Due To Pseudomonas Aeruginosa" Phase II (completed).

[5] "A Study to Determine the Safety and Tolerability of Arikace™ Versus Placebo in Patients Who Have Bronchiectasis" Архивирано на сајту Wayback Machine (29. април 2015) is a Phase II clinical trial (as [4]) completed in the UK.

[1]

[2]

[3]

[4]

[5]